Excerpt from OncLive:
“Treatment with apalutamide (Erleada) was not associated with a significant impact on health-related quality of life (HRQoL) in patients with high-risk nonmetastatic castration-resistant prostate cancer, according to patient-reported outcome (PRO) data from the phase III SPARTAN trial.
“In the study overall, patients treated with the addition of apalutamide to standard hormone therapy also had an improvement in metastasis-free survival (MFS) and longer time to symptomatic progression compared with those who were treated with placebo.”
Go to full article published by OncLive on Sep 17, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.